Identification |
Name: | Benzamide,5-chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- |
Synonyms: | 5-Chloro-2-[[(5-chlorothien-2-yl)sulfonyl]amino]-N-[4-[(morpholin-4-yl)sulfonyl]phenyl]benzamide;Ataciguat; HMR 1766 |
CAS: | 254877-67-3 |
Molecular Formula: | C21H19 Cl2 N3 O6 S3 |
Molecular Weight: | 0 |
InChI: | InChI=1/C21H19Cl2N3O6S3/c22-14-1-6-18(25-34(28,29)20-8-7-19(23)33-20)17(13-14)21(27)24-15-2-4-16(5-3-15)35(30,31)26-9-11-32-12-10-26/h1-8,13,25H,9-12H2,(H,24,27) |
Molecular Structure: |
|
Properties |
Flash Point: | °C |
Boiling Point: | °Cat760mmHg |
Density: | 1.613g/cm3 |
Refractive index: | 1.684 |
Flash Point: | °C |
Usage: | Ataciguat, formerly referred to as HMR-1766, a novel anthranilic acid derivative, belongs to a new structural class of sGC activators capable of activating the oxidized form of sGC. Ataciguat has been shown to improve endothelial function and to reduce p |
Safety Data |
|
|